Endocrinopathies in patients with thalassemias

Saudi Medical Journal

Volumn 25, Issue 10, 2004, Pages 1347-1351

  Al Elq, Abdulmohsen H ^a   Al Saeed, Hussain H ^b  

^a IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^b QATIF CENTRAL HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CHELATING AGENT; CHORIONIC GONADOTROPIN; CONJUGATED ESTROGEN; DEFEROXAMINE; ESTROGEN; GLUCOCORTICOID; GONADORELIN; HUMAN MENOPAUSAL GONADOTROPIN; INSULIN; LEVOTHYROXINE; MEDROXYPROGESTERONE; MINERALOCORTICOID; ORAL ANTIDIABETIC AGENT; PROGESTERONE; RECOMBINANT GROWTH HORMONE; VITAMIN D;

ADRENAL DISEASE; ANEMIA; BLOOD TRANSFUSION; DIABETES MELLITUS; DISEASE SEVERITY; ENDOCRINE DISEASE; ENDOCRINE GLAND; GENETIC DISORDER; GLUCOSE METABOLISM; GROWTH DISORDER; HEART; HEMOGLOBIN SYNTHESIS; HUMAN; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; IRON OVERLOAD; IRON STORAGE; LIFE EXPECTANCY; LIVER; REVIEW; THALASSEMIA MAJOR; TISSUE INJURY;

ADRENAL INSUFFICIENCY; BETA-THALASSEMIA; BLOOD GLUCOSE; COMORBIDITY; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; MALE; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SAUDI ARABIA; SEVERITY OF ILLNESS INDEX;

EID: 7244247360     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Piomelli S. Management of Cooley's anaemia. Baillieres Clin Haematol 1993; 6: 287-298.
2. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331: 574-578.
3. De Sanctis V, Stea S, Savarino L, Scialpi V, Traina GC, Chiarelli GM et al. Growth hormone secretion and bone histomorphometric study in thalassemic patients with acquired skeletal dysplasia secondary to desferrioxamine. J Pediatr Endocrinol Metab 1998; 11 Suppl 3: 827-833.
4. Jensen CE, Tuck SM, Old J, Morris RW, Yardumian A, De Sanctis V et al. Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia. Eur J Haematol 1997; 59: 76-81.
5. Kuhn-Velten WN, Pippirs U. Novel connections between NADPH-induced lipid peroxidation and cytochrome P450 inactivation, and antioxidant and enzyme protective properties of estradiol in gonadal membranes. Free Radic Res 1997; 26: 125-133.
6. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major. N Engl J Med 1990; 323: 713-719.
7. Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. Arch Intern Med 1985; 145: 1217-1221.
8. Kattamis C, Metaxotou-Mavromati A, Ladis V, Tsiarta H, Laskari S, Kanavakis E. The clinical phenotype of beta and delta beta thalassemias in Greece. Eur J Pediatr 1982; 139: 135-138.
9. Kattamis C, Hu H, Cheng G, Reese AL, Gonzalez-Redondo JM, Kutlar A et al. Molecular characterization of beta-thalassemia in 174 Greek patients with thalassemia major. Br J Haematol 1990; 74: 342-346.
10. Pintor C, Cella SG, Manso P, Corda R, Dessi C, Locatelli V et al. Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major. J Clin Endocrinol Metab 1986; 62: 263-267.
11. Ambrosetto P, Zucchini S, Cicognani A, Cacciari E. MR findings in pituitary haemosiderosis. Pediatr Radiol 1998; 28: 288-289.
12. Kattamis C, Touliatos N, Haidas S, Matsaniotis N. Growth of children with thalassemia: effect of different transfusion regimens. Arch Dis Child 1970; 45: 502-509.
13. Logothetis J, Lowenson RB, Augoustaki O, Economidou J, Constantoulakis M. Body growth in Cooley's anemia (homozygous beta-thalassemia) with a correlative study as to other aspects of illness in 138 cases. Pediatrics 1972; 50: 92-99.
14. Vannasaeng S, Fucharoen S, Pootrakul P, Ploybutr S, Yansukon P. Pituitary functions in thalassemic patients and the effect of chelation therapy. Acta Endocrinol (Copenh) 1991; 124: 23-30.
15. Roth C, Pekrun A, Bartz M, Jarry H, Eber S, Lakomek M et al. Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr 1997; 156: 777-783.
16. Kattamis C, Liakopoulu T, Kattamis A. Growth and development in children with thalassemia major. Acta Paediatr Scand Suppl 1990; 366: 111-117.
17. Borgna-Pignatti C, De Stefano P, Zonta L, Vullo C, De Sanctis V, Melevendi C et al. Growth and sexual maturation in thalassemia major. J Pediatr 1985; 106: 150-155.
18. Theodoridis C, Ladis V, Papatheodorou A, Berdousi H, Palamidou F, Evagelopoulou C, et al Growth and management of short stature in thalassaemia major. J Pediatr Endocrinol Metab 1998; 11 Suppl 3: 835-844.
19. De Sanctis V, Vullo C, Katz M, Wonke B, Tanas R, Bagni B. Gonadal function in patients with β-thalassemia major. J Clin Pathol 1988; 41: 133-137.
20. De Sanctis V, Vullo C, Katz M, Wonke B, Hoffbrand AV, Bagni B. Hypothalamic-pituitary-gonadal axis in thalassemic patients with secondary amenorrhea. Obstet Gynecol 1988; 72: 643-647.
21. Upreti GC, Jensen K, Oliver JE, Duganzich DM, Munday R, Smith JF. Motility of ram spermatozoa during storage in chemically-defined diluent containing antioxidants. Anim Reprod Sci 1997; 48: 269-278.
22. De Sanctis V. Growth and puberty and its management in thalassaemia. Horm Res 2002; 58 Suppl 1: 72-79.
23. Balducci R, Toscano V, Finocchi G, Municchi G, Mangiantini A, Boscherini B. Effect of hCG or hCG+ treatments in young thalassemic patients with hypogonadotropic hypogonadism. Eur J Clin Invest 1990; 13: 1-7.
24. Moura MD, Navarro PA, Silva de Sa MF, Ferriani RA, Unzer SM, Reis RM. Hypogonadotropic hypogonadism: retrospective analysis of 19 cases. Int J Gynaecol Obstet 2000; 71: 141-145.
25. Chatterjee R, Katz M. Reversible hypogonadotrophic hypogonadism in sexually infantile male thalassaemic patients with transfusional iron overload. Clin Endocrinol (Oxf) 2000; 53: 33-42.
26. Farina G, Pedrotti C, Cerani P, Rovati A, Strada E, Bergamaschi G, et al Successful pregnancy following gonadotropin therapy in a young female with juvenile idiopathic hemochromatosis and secondary hypogonadotropic hypogonadism. Haematologica 1995; 80: 335-337.
27. Jensen CE, Tuck SM, Wonke B. Fertility in beta thalassaemia major: a report of 16 pregnancies, preconceptual evaluation and a review of the literature. Br J Obstet Gynaecol 1995; 102; 625-629.
28. Tuomainen TP, Nyyssonen K, Salonen R, Tervahauta A, Korpela H, Lakka T, et al Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men. Diabetes Care 1997; 20: 426-428.
29. Merkel PA, Simonson DC, Amiel AS, Plewe G, Sherwin RS, Pearson HA, et al Insulin resistance and hyperinsulinemia in patients with thalassemia major, treated by hypertransfusion. N Engl J Med 1988; 318: 809-814.
30. Cario H, Holl RW, Debatin KM, Kohne E. Insulin sensitivity and beta-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test. Eur J Pediatrics 2003; 162: 139-146.
31. Chern JP, Lin KH, Lu MY, Lin DT, Lin KS, Chen JD, et al. Abnormal glucose tolerance in transfusion-dependent beta-thalassemic patients. Diabetes Care 2001; 24: 850-854.
32. De Sanctis V, Zurlo MG, Senesi E, Boffa C, Cavallo L, Di Gregorio F. Insulin dependent diabetes mellitus in thalassemia. Arch Dis Child 1988; 51: 828-832.
33. Capra L, Atti G, De Sanctis V, Candini G. Glucose tolerance and chelation therapy in patients with thalassaemia major. Haematologica 1983; 68: 63-68.
34. Loebstein R, Lehotay DC, Luo X, Bartfay W, Tyler B, Sher GD. Diabetic nephropathy in hypertransfused patients with beta-thalassemia. The role of oxidative stress. Diabetes Care 1998; 21: 1306-1309.
35. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573.
36. Landau H, Matoth I, Landau-Cordova Z, Goldfarb A, Rachmilewitz EA, Glaser B. Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassaemia major. Clin Endocrin 1993; 38: 55-61.
37. Anonymous. Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Clin Endocrin 1995; 42: 581-586.
38. Agarwal MB, Shah S, Vishwanathan C, Rajadhyaksha G, Bhave AA, Dube SR, et al. Thyroid dysfunction in multi-transfused iron loaded thalassemia patients. Indian Pediatr 1992; 29: 997-102.
39. Magro S, Puzzonia P, Consarino C, Galati MC, Morgione S, Porcelli D, et al. Hypothyroidism in patients with thalassemia syndromes. Acta Haematologica 1990; 84: 72-76.
40. De Sanctis V, Vullo C, Bagni B, Chiccoli L. Hypoparathyroidism in beta-thalassemia major. Clinical and laboratory observations in 24 patients. Acta Haematol 1992; 88: 105-108.
41. Chern JP, Lin KH. Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia. J Pediatr Hematol Oncol 2002; 24: 291-293.
42. Aloia JF, Ostuni JA, Yeh JK, Zaino EC. Combined vitamin D parathyroid defect in thalassemia major. Arch Intern Med 1982; 142: 831-832.
43. Sklar CA, Lew LQ, Yoon DJ, David R. Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion. Am J Dis Child 1987; 141: 327-330.